India's Dr Reddy's logs worst week in 3 years as semaglutide disruption fuels growth concerns
BUZZ-India's Dr Reddy's logs worst week in 3 years as semaglutide disruption fuels growth concerns Updates
** Dr Reddy's Laboratories REDY.NS closed 1.8% down at 1246.5 rupees, down as much as 3.7% in the session
** Stock logs second straight day of losses; down 9.3% over the week, biggest weekly drop since May 2023
** Co reported on Thursday that supplies of generic semaglutide would remain unavailable in India and face disruptions in Canada due to impurities in API, until late October at least
** Systematix downgrades REDY to "hold", believes execution risk remains, with possibility of further delays
** Emkay Global ("reduce", PT 1,300 rupees) cuts FY27 earnings estimates by 7% as prior margin assumptions "now seem out of reach"
** REDY rated "hold" on avg by 38 analysts; median PT 1,300 rupees - data compiled by LSEG
** Torrent Pharmaceuticals TORP.NS, which sources finished semaglutide doses from REDY, down 2.3%
** REDY down 2% YTD
(Reporting by Abhirami G in Bengaluru)
Recent news on Torrent Pharmaceuticals
See all newsHSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Brief: Torrent Pharma Q2 Consol Net Profit 5.34 Billion Rupees
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says